Physician profile
Grant Ingalls
NPI 1487271045
$7,060.33
in general payments reported to CMS, 2019-2025
23 companies · $4,019 in 2025
The $4,019 reported for 2025 was more than what 98% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $303 · 2024: $2,738 · 2025: $4,019.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,888 · Education: $172.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,888.35 |
| Education | $171.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $1,868.17 | 2023-2025 | Tremfya, Simponi Aria |
| Abbvie INC. | $1,390.74 | 2023-2025 | |
| Amgen INC. | $808.58 | 2023-2025 | Krystexxa, Otezla, Enbrel |
| Ucb, INC. | $717.85 | 2024-2025 | Bimzelx, Cimzia |
| Pfizer INC. | $543.60 | 2024-2025 | |
| Astrazeneca Pharmaceuticals LP | $295.00 | 2024-2025 | Saphnelo |
| E.R. Squibb & Sons, L.L.C. | $278.94 | 2024-2025 | Orencia |
| Ani Pharmaceuticals, INC. | $140.69 | 2024-2025 | Purified Cortrophin Gel |
| Fresenius Kabi USA, LLC | $136.94 | 2024-2025 | Idacio |
| Organon LLC | $133.82 | 2024-2025 | Renflexis, Hadlima |
| Sobi, INC | $124.34 | 2024-2025 | |
| Novartis Pharmaceuticals Corporation | $115.37 | 2024-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $104.94 | 2024-2025 | Ofev, Cyltezo |
| Lilly USA, LLC | $104.63 | 2024-2025 | Taltz |
| Sandoz INC. | $61.23 | 2024 | Hyrimoz |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vertex Pharmaceuticals Incorporated | $45.28 | 2025 | |
| Kiniksa Pharmaceuticals International, Plc | $42.37 | 2024 | Arcalyst |
| Kyowa Kirin, INC. | $40.88 | 2025 | |
| Spr Therapeutics, INC | $27.35 | 2025 | Sprint Pns System |
| Mallinckrodt Hospital Products INC. | $22.64 | 2025 | Acthar |
| Glaxosmithkline, LLC. | $22.01 | 2025 | Benlysta |
| Halozyme INC | $18.27 | 2023 | |
| Ferring Pharmaceuticals INC. | $16.69 | 2025 | Euflexxa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Grant Ingalls listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.